SGEN News and Press, Seagen Inc.

2024-02-26 13:48:44 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In a volatile market, many investors follow the strategy of chasing their winners higher. Money has flooded stocks such as Nvidia (NASDAQ: NVDA ). However, many of these stocks ...

2024-02-12 08:57:56 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The risk-on sentiment is returning, with the market closing at new record highs daily. That means many investors are steering clear of dividend stocks . This is particularly true of div...

2024-02-01 12:22:12 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Interestingly, there are no Big Pharma companies listed in the “Magnificent Seven.” Consequently, perfectly good companies like Pfizer (NYSE: PFE ) are being over...

2024-01-29 12:15:22 ET More on Pfizer Why I'm Avoiding 6%-Yielding Pfizer Stock Pfizer: CEO Bets His Pension On The Stock - Upgrading To Buy Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Pfizer wins NICE nod for breast cancer therapy Talzenna ...

2024-01-17 07:08:09 ET More on Pfizer Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Pfizer Inc. (PFE) J.P. Morgan 42nd Annual Healthcare Conference (Transcript) Pfizer: 50% Down From The Highs, Generous Dividend, And Robust Balance Sheet First RSV...

2024-01-08 07:52:26 ET More on Johnson & Johnson Johnson & Johnson: Overblown Stelara Concerns Distract From Value Johnson & Johnson's Bullish Outlook: Surprising Strength You Shouldn't Overlook Johnson & Johnson: A Defensive Dividend King Set To Outp...

2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...

2024-01-06 05:10:52 ET Summary Pfizer has generally paid high prices for M&A, above industry norms (20x vs 10x EV/Revenue deal multiples). Oncology has been a lagging business for Pfizer despite being a hot growth area (1.5% 3-yr CAGR for Oncology vs 4.5% 3-yr CAGR for non-COV...

2024-01-02 11:12:57 ET Summary Madrigal Pharmaceuticals, Inc. stock has rallied 70% since late October due to a decrease in competitive concerns and a large secondary offering. The company's candidate resmetirom is expected to be the first approved therapy for NASH in March 2024. ...

2023-12-29 10:48:17 ET More on Pfizer The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Pfizer: Buy The Panic Pharma and biotech deal values spike 35% ...